So in our AIS of HEARTS study, we included almost 4,000 patients with acute ischemic stroke that underwent cardiac CT acquired during the acute stroke protocol. And cardiac CT detected a cardiac thrombus in approximately 6% of patients with ischemic stroke. And the yield was around seven times higher compared to TTE, transthoracic echocardiography. So when we looked at the 90-day follow-up, we compared patients with a cardiac thrombus versus patients without a cardiac thrombus, and we detected that patients with a cardiac thrombus had a higher mortality, a higher risk of MACE, so major adverse cardiovascular events, and a worse functional outcome compared to patients without a cardiac thrombus...
So in our AIS of HEARTS study, we included almost 4,000 patients with acute ischemic stroke that underwent cardiac CT acquired during the acute stroke protocol. And cardiac CT detected a cardiac thrombus in approximately 6% of patients with ischemic stroke. And the yield was around seven times higher compared to TTE, transthoracic echocardiography. So when we looked at the 90-day follow-up, we compared patients with a cardiac thrombus versus patients without a cardiac thrombus, and we detected that patients with a cardiac thrombus had a higher mortality, a higher risk of MACE, so major adverse cardiovascular events, and a worse functional outcome compared to patients without a cardiac thrombus. However, the risk of a recurrent stroke was similar between groups. However, our study remained an observational study so also for the outcome reporting we were dependent on routine clinical care so there may be an underestimation of recurrent stroke reported and also there are no clear treatment guidelines on what to do once you detect a cardiac thrombus. But clinicians generally start with anticoagulation when a cardiac thrombus is detected, even in the absence of atrial fibrillation. So that might have also decreased the recurrent stroke risk. But other than that, the fact that we found a higher mortality and worse functional outcome in this group at follow-up still provides us with important prognostic information. And there may be opportunities within this group to discover other therapeutic options. And also, for example, the type of anticoagulation, the timing of starting and the duration of the anticoagulation is still unclear so definitely we need larger clinical trials on that subject to discover what is the best therapeutic options for this group.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.